Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis

Inflammatory Bowel Diseases

Volumn 14, Issue 11, 2008, Pages 1611-1613

  Ermis, Fatih ^a   Ozdil, Sadakat ^a   Akyüz, Filiz ^a   Pinarbasi, Binnur ^a   Mungan, Zeynel ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE; MONOCLONAL ANTIBODY;

ADULT; CASE REPORT; COLONOSCOPY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG REEXPOSURE; DRUG RESPONSE; DRUG TOLERABILITY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOCHEZIA; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REPEATED DRUG DOSE; SKIN BIOPSY; SKIN DEFECT; SKIN ULCER; TREATMENT DURATION; ULCERATIVE COLITIS; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; PYODERMA GANGRENOSUM; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 59249105181     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20481     Document Type: Letter

References (8)

1. Von den Driesch. Pyoderma gangrenosum: a report of 44 cases with follow up. Br J Dermatol. 1997;137:1000-1005.
2. Ljung P, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockage with Infliximab. Scand J Gastroenterol. 2002;37:1108-1110.
3. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821-1826.
4. Zaccagna A, Bertone A, Puiatti P, et al. Antitumour necrosis factor alpha monoclonal antibody (infliximab) for the treatment of pyoderma gangrenosum associated with Crohn's disease. Eur J Dermatol. 2003;13:258-260.
5. Broklyn TN, Dunnill MGS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505-509.
6. Sapienza MS, Cohen S, Dimarino AJ. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci. 2004; 49:1454-1457.
7. De la Morena F, Martin L, Gispert JP, et al. Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab. Inflamm Bowel Dis. 2007;13:509-510.
8. Juillerat P, Christen-Zach S, Troillet FX, et al. Infliximab for the treatment of disseminated pyodrma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology. 2007;215:245-251.